Vixarelimab

In 2023, systemic sclerosis market size was USD 1,850M in 7MM, with the US leading. Italy had the largest market in EU4 and UK. The US also had the highest diagnosed cases. Treatments like OFEV and ACTEMRA are approved, but Rituximab showed significant improvements. Emerging therapies, including CAR-T cell therapies, are in development, promising future growth. The disease's severity varies by organ involvement, with lung disease being a major concern.

The Systemic Sclerosis Treatment Market is projected to grow significantly by 2034, driven by increasing prevalence, awareness, and FDA approvals like CABA-201's Orphan Drug and Fast Track Designations. Key players include Kyowa Hakko Kirin, AstraZeneca, and others, with therapies such as LUMICEF and SAPHNELO leading the pipeline. The market's expansion is also fueled by ongoing clinical trials and the development of new treatments targeting systemic sclerosis and related conditions.

DelveInsight's report forecasts an increase in Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) cases by 2034, highlighting the UK's highest prevalence. With 83% of 64,000 cases diagnosed in 2023, there's a call for better screening. Females are more affected, and severe cases account for 30%. Emerging therapies like Mycophenolate mofetil and Nintedanib are promising, with companies like Genentech and Boehringer Ingelheim leading the market.